Madhuri Paul

University of California, Irvine — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index46citations85works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(50), Multiple Myeloma Research and Treatments(36), Peptidase Inhibition and Analysis(22), Cancer, Lipids, and Metabolism(20), Chemokine receptors and signaling(18)

Publications84 total

Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis
Blood·2025
Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate
2025Open Access
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response
Leukemia·2025· 7 citedOpen Access
Resource acquisition and interactions in spring wheat/faba bean intercropping under diverse environments
Field Crops Research·2025· 2 citedOpen Access
Pitavastatin Potentiates Mitochondrial Dysfunction and Venetoclax Cytotoxicity in Acute Myeloid Leukemia Cells
Blood·2024
Evaluating a new intercrop model for capturing mixture effects with an extensive intercrop dataset
Agriculture Ecosystems & Environment·2024· 2 citedOpen Access
Correction to: Root growth and belowground interactions in spring wheat /faba bean intercrops
Plant and Soil·2024· 1 citedOpen Access
Chemoresistance of <i>TP53</i> mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response
2024Open Access
Root growth and belowground interactions in spring wheat /faba bean intercrops
Plant and Soil·2024· 8 citedOpen Access
Figure S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S6 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S13 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Data from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 2 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S3 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 7 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Roberta Buono(39), Roberta Buono(36), Dennis Juarez(33), Shannon M. Matulis(32), Vikas A. Gupta(32), Madeleine Duong(32), Jacob Yudiono(32), Sharmila Mallya(32), Grace Diep(32), Peter Hsin(32), Alexander Lu(32), Sang Mi Suh(32), Vy M. Dong(32), Andrew W. Roberts(32), Joel Johansson(32), Muhammad Jalaluddin(32), Zhuangzhuang Liu(32), Orlando F. Bueno(32), Lawrence Boise(32), Thomas Döring(4)